Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... ATLANTA, Dec. 11 WellCentive ( http://www.wellcentive.com ),today ... information technology (HIT),solutions designed to efficiently, securely and ... care providers. WellCentive Gateway allows,providers, such as ... variety of,outside HIT systems. WellCentive Connect is ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... passed away on Wednesday. Dr. Waltz had been a director ... the time of his death, Dr. Waltz served on Peregrine,s Audit ... , "The sudden loss of our business colleague ...
... - SCRIP Awards Recognises the Best and Brightest in ... - Glenmark is the Only Indian Company to ... The best and brightest of ... London at the 2008 SCRIP Awards hosted,by the leading UK broadcaster ...
Cached Biology Technology:WellCentive Launches New Health Information Exchange Platforms 2WellCentive Launches New Health Information Exchange Platforms 3Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2
(Date:4/17/2014)... of The Proceedings of the National ... 29, raises a number of startling questions about a ... take for granted. At the end of the last ... shifted from hunting animals and gathering fruits and tubers ... straightforward and yet the more scientists learn, the more ...
(Date:4/16/2014)... TALLAHASSEE, Fla. Florida State University researchers have identified ... deterioration of bone density and muscle mass with obesity. ... heavier you were the better your bones would be ... Ilich-Ernst, the Hazel Stiebeling Professor of Nutrition at Florida ...
(Date:4/16/2014)... Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is a ... and atrophy. Researchers have long considered it to be essentially ... the spinal cord and brainstem that control muscle movement. , ... 2014 online issue of Neuron , a team of ...
Breaking Biology News(10 mins):Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4Researchers: Obesity can amplify bone and muscle loss 2Mutant protein in muscle linked to neuromuscular disorder 2
... A new study by researchers at NYU School of Medicine ... cells, causing mutations that can lead to melanoma. ... skin to protect it from the ultraviolet rays of the ... cells because they are unable to repair themselves as efficiently. ...
... been hearing about ESA,s most recently launched mission, CryoSat-2. ... in excellent health with scientists very encouraged by the ... Duncan Wingham, Lead Investigator for the CryoSat mission, stated, ... in-orbit specifications, the ground segment software is fine, the ...
... A new study from researchers in Ottawa and Toronto ... cell may be able to help treat sepsis, a deadly ... body. The study, published in the American Journal of ... can triple survival rates in an experimental model of sepsis. ...
Cached Biology News:UVA radiation damages DNA in human melanocyte skin cells and can lead to melanoma 2CryoSat-2 exceeding expectations 2Stem-cell therapy may provide new approach to fight infection 2
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
Biology Products: